Taysha Gene Therapies (TSHA) Net Cash Flow (2020 - 2026)

Taysha Gene Therapies has reported Net Cash Flow for 7 years, with the latest figure at -$43.2 million in Q1 2026.

• Quarterly Net Cash Flow fell 92.45% year-over-year to -$43.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.1 million (up 2267.96% YoY) and the FY2025 annual result came in at $180.9 million, up 3788.72% from the prior year.
• Net Cash Flow fell to -$43.2 million in Q1 2026 per TSHA's latest filing, from $22.6 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $196.2 million in Q2 2025 and troughed at -$52.5 million in Q1 2022.
• A 5-year average of $7.5 million and a median of -$18.7 million in 2024 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 473.27% in 2023, down 138.03% in 2023.
• Over 5 years, Net Cash Flow stood at $53.6 million in 2022, then slumped by 138.03% to -$20.4 million in 2023, then climbed by 8.46% to -$18.7 million in 2024, then jumped by 221.1% to $22.6 million in 2025, then sank by 291.22% to -$43.2 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$43.2 million, $22.6 million, and -$15.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.